Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 1

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 1
---
 Company has two commercial products, HEPLISAV - B® vaccine hepatitis B Vaccine (Recombinant), Adjuvanted, which is approved in the U.S., the European Union and the United Kingdom for t he prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV - B and multiple adjuvanted COVID - 19 vaccines. For more information abou t our marketed products and development pipeline, visit www.dynavax.com. Forward - Looking Statements This presentation contains “forward - looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amen ded, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward - looking statements. Forward - looking stateme nts can generally be identified by the use of words such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “will,” “may,” “plan,” “potential,” “seek,” “would” and similar expressions, or the negatives thereof, or th ey may use future dates. Forward - looking statements made in this document include statements regarding the Company’s submission of a declassification proposal at its 2025 Annual Meeting, expected contributions from newly appointed d ire ctors, expectations regarding delivering value for our stockholders, our future growth, market share, expected product revenue and long - term performance . Actual results may differ materially from those set forth in this presentat ion due to the risks and uncertainties inherent in our business, including, the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change, risks relating to our ability to commercialize and supply HE PLI SAV - B, and risks related to the implementation of our long - term growth objectives, as well as other risks detailed in the “Risk Factors” section of our Quarterly Report on Form 10 - Q for the three months ended March 31, 2025 and any pe riodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward - looking statements are made as of t he date hereof, are qualified in their entirety by this cautionary statement and we undertake